Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index easing 0.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) fractionally higher.
The iShares Biotechnology ETF (IBB) decreased 0.7%.
In corporate news, Prestige Consumer Healthcare's (PBH) officials said Thursday that weak eye care sales and a difficult consumer backdrop drove disappointing fiscal Q4 results at the consumer healthcare products company. Its shares were down past 11%.
Biogen (BIIB) shares fell nearly 7% after the firm said Thursday that a phase 2 trial of diranersen in people with early Alzheimer's disease did not meet its primary endpoint.
Doximity (DOCS) could face near-term pressure from slowing growth after issuing weaker-than-expected guidance, though strong user engagement trends and expanding AI opportunities continue to support the stock's long-term outlook, Morgan Stanley said in a note. Morgan Stanley lowered the price target on Doximity to $35 from $49, while maintaining an overweight rating. Doximity shares dropped more than 23%.
Aveanna Healthcare (AVAH) shares jumped past 8% after it reported higher fiscal Q1 adjusted earnings and revenue, and raised its fiscal 2026 revenue guidance.